» Articles » PMID: 31128571

A High C-reactive Protein/procalcitonin Ratio Predicts Mycoplasma Pneumoniae Infection

Overview
Specialties Biochemistry
Pathology
Date 2019 May 26
PMID 31128571
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background Discriminating Mycoplasma pneumoniae (MP) from Streptococcus pneumoniae (SP) and viral etiologies of community-acquired pneumonia (CAP) is challenging but has important implications regarding empiric antibiotic therapy. We investigated patient parameters upon hospital admission to predict MP infection. Methods All patients hospitalized in a tertiary care hospital between 2013 and 2017 for CAP with a confirmed etiology were analyzed using logistic regression analyses and area under the receiver operator characteristics (ROC) curves (AUC) for associations between demographic, clinical and laboratory features and the causative pathogen. Results We analyzed 568 patients with CAP, including 47 (8%) with MP; 152 (27%) with SP and 369 (65%) with influenza or other viruses. Comparing MP and SP by multivariate logistic regression analysis, younger age (odds ration [OR] 0.56 per 10 years, 95% CI 0.42-0.73), a lower neutrophil/lymphocyte ratio (OR 0.9, 0.82-0.99) and an elevated C-reactive protein/procalcitonin (CRP/PCT) ratio (OR 15.04 [5.23-43.26] for a 400 mg/μg cut-off) independently predicted MP. With a ROC curve AUC of 0.91 (0.80 for the >400 mg/μg cutoff), the CRP/PCT ratio was the strongest predictor of MP vs. SP. The discriminatory value resulted from significantly lower PCT values (p < 0.001) for MP, while CRP was high in both groups (p = 0.057). Comparing MP and viral infections showed similar results with again the CRP/PCT ratio providing the best information (AUC 0.83; OR 5.55 for the >400 mg/μg cutoff, 2.26-13.64). Conclusions In patients hospitalized with CAP, a high admission CRP/PCT ratio predicts M. pneumoniae infection and may improve empiric management.

Citing Articles

Study of the Role of C-reactive Protein/Procalcitonin Ratio as a Prognostic Tool in ICU Patients with Sepsis: A Prospective Observational Study.

Abdellatif E, Hamouda E Indian J Crit Care Med. 2025; 28(12):1130-1138.

PMID: 39759787 PMC: 11695878. DOI: 10.5005/jp-journals-10071-24855.


The predictive values of C-reactive protein-neutrophil to lymphocyte ratio for the risk of refractory pneumonia in children: a retrospective cohort study.

Chen X, Wang S, Cai H, Xia X Epidemiol Infect. 2024; 152:e158.

PMID: 39635861 PMC: 11648507. DOI: 10.1017/S0950268824001134.


Research status and challenges of Mycoplasma pneumoniae pneumonia in children: A bibliometric and visualization analysis from 2011 to 2023.

Liu C, Wang R, Ge S, Wang B, Li S, Yan B Medicine (Baltimore). 2024; 103(11):e37521.

PMID: 38489686 PMC: 10939570. DOI: 10.1097/MD.0000000000037521.


Factors affecting 90-day mortality in community and hospital acquired pneumonia patients with or without acute kidney injury.

Hosgun D, Aydemir S Afr Health Sci. 2023; 22(3):567-577.

PMID: 36910350 PMC: 9993250. DOI: 10.4314/ahs.v22i3.61.


The Risk and Clinical Implications of Antibiotic-Associated Acute Kidney Injury: A Review of the Clinical Data for Agents with Signals from the Food and Drug Administration's Adverse Event Reporting System (FAERS) Database.

Clifford K, Selby A, Reveles K, Teng C, Hall 2nd R, McCarrell J Antibiotics (Basel). 2022; 11(10).

PMID: 36290024 PMC: 9598234. DOI: 10.3390/antibiotics11101367.